Elizabeth Jenny-Avital
Internal Medicine · Bronx, NYNPI 1730260811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,925 of the $185,114 with a category attached, or 85.3%. Gilead accounts for 60.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $63,519 and has fallen 84.7% since, to $9,695 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $555.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$113K
- Viiv Healthcare Company$70K
- GSK$1K
- Theratechnologies Inc.$750
- Boehringer Ingelheim$241
- Janssen Scientific Affairs, LLC$128
What the payments were for
- Consulting fees$4,5202%
- Speaking & faculty fees$157,92585%
- Travel & lodging$16,3409%
- Food & beverage$6,3293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 181 | $112,645 |
| Viiv Healthcare Company | 140 | $70,321 |
| GSK | 8 | $1,029 |
| Theratechnologies Inc. | 1 | $750 |
| Boehringer Ingelheim | 2 | $241 |
| Janssen Scientific Affairs, LLC | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,114 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 380 | $1,421,297 |
| DescovyEmtricitabine/Tenofov Alafenam | 188 | $414,117 |
| TivicayDolutegravir Sodium | 167 | $392,585 |
| JulucaDolutegravir/Rilpivirine | 69 | $224,492 |
| CabenuvaCabotegravir/Rilpivirine | 19 | $114,504 |
| DovatoDolutegravir Sodium/Lamivudine | 34 | $97,069 |
| OzempicSemaglutide | 63 | $61,655 |
| EdurantRilpivirine Hcl | 28 | $48,614 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $44,085 |
| PifeltroDoravirine | 15 | $24,640 |
| PrezistaDarunavir | 11 | $21,946 |
| JardianceEmpagliflozin | 24 | $14,797 |
| XareltoRivaroxaban | 17 | $12,553 |
| Atrovent HfaIpratropium Bromide | 12 | $5,213 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $112,645 | $1,835,414568 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Dovato | $70,321 | $828,650289 claims |
| Janssen Scientific Affairs, LLCEdurant, Prezista | $128 | $70,56039 claims |
| Boehringer IngelheimJardiance | $241 | $14,79724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.